The generic drug trilemma
Year of publication: |
2023
|
---|---|
Authors: | Hemel, Daniel J. ; Ouellette, Lisa Larrimore |
Published in: |
Entrepreneurship and innovation policy and the economy : EIPE. - Getzville, NY : HeinOnline, ISSN 2771-1676, ZDB-ID 3121436-8. - Vol. 2.2023, p. 41-77
|
Subject: | drug pricing | drug quality | drug shortages | generics | pharmaceutical manufacturing | pharmaceutical policy | Osteuropa | Eastern Europe | Arzneimittel | Pharmaceuticals | Generika | Generic drugs | Pharmaindustrie | Pharmaceutical industry | Arzneimittelmarkt | Pharmaceutical market | Arzneimittelrecht | Pharmaceutical law | Droge | Drug | Preisregulierung | Price regulation | Preis | Price | Gesundheitskosten | Health care costs | Drogenkonsum | Drug consumption |
-
Empirical evidence of risk penalties for NTI Drugs
Gentry, Elissa Philip, (2019)
-
Pharmaceuticals industry and regulation in India : a note
Motkuri, Venkatanarayana, (2018)
-
The interaction between leading drugs and pharmacy-owned labels in Chile
Escobar E., Gonzalo, (2023)
- More ...
-
What Role Should Governments Play in Setting Rewards for Medical Innovation?
Ouellette, Lisa Larrimore, (2021)
-
Beyond the Patents-Prizes Debate
Hemel, Daniel J., (2014)
-
Knowledge Goods and Nation-States
Hemel, Daniel J., (2016)
- More ...